Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Birch

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44335   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    96 result(s) found for: Birch. Displaying page 1 of 5.
    1  2  3  4  5  Next»
    EudraCT Number: 2016-000076-23 Sponsor Protocol Number: AN006T-ATIBAR Start Date*: 2016-07-27
    Sponsor Name:ANERGIS SA
    Full Title: A MULTICENTRE, DOUBLE-BLIND, PLACEBO-CONTROLLED, RANDOMIZED TRIAL TO ASSESS THE EFFICACY AND TOLERABILITY OF TWO DOSING REGIMENS OF ALLERT, A COMBINATION OF CONTIGUOUS OVERLAPPING PEPTIDES DERIVED ...
    Medical condition: Adult patients, 18-65 years of age, suffering from moderate to severe allergic Rhinitis/Rhinoconjunctivitis to birch pollen during the two preceding birch pollen seasons.
    Disease: Version SOC Term Classification Code Term Level
    19.1 100000004870 10066093 Birch pollen allergy LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SK (Completed) LT (Completed) DE (Completed) DK (Completed) FI (Completed)
    Trial results: (No results available)
    EudraCT Number: 2005-000025-35 Sponsor Protocol Number: Al0204AV Start Date*: 2005-04-05
    Sponsor Name:Allergopharma Joachim Ganzer KG
    Full Title: A multicentre randomised placebo-controlled double-blind clinical trial for evaluation of safety and efficacy of specific immunotherapy with an aluminium hydroxide-adsorbed allergoid preparation of...
    Medical condition: IgE-mediated allergic diseases including allergic rhinitis/rhinoconjunctivitis, allergic bronchial asthma (GINA I and II) triggered by birch pollen allergens
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed) FI (Completed) SE (Completed)
    Trial results: View results
    EudraCT Number: 2012-000031-59 Sponsor Protocol Number: TT-02 Start Date*: 2012-09-12
    Sponsor Name:ALK-Abelló A/S
    Full Title: A dose-response evaluation of ALK tree AIT
    Medical condition: Subjects with a documented clinically relevant history of moderate to severe birch pollen induced allergic rhinoconjunctivitis (with or without asthma) with symptoms despite having received symptom...
    Disease: Version SOC Term Classification Code Term Level
    16.0 100000004870 10066093 Birch pollen allergy LLT
    Population Age: Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: LT (Completed) FI (Completed) NO (Completed) SE (Completed) NL (Completed) PL (Completed) DK (Completed)
    Trial results: View results
    EudraCT Number: 2022-002012-23 Sponsor Protocol Number: SL79.22 Start Date*: Information not available in EudraCT
    Sponsor Name:STALLERGENES
    Full Title: A Multi-national Phase IIIb, Double-blind, Placebo-controlled Trial to Determine the Safety and Efficacy of STALORAL® Birch 300 IR in Children and Adolescents 5 to 17 Years old with Birch Pollen-in...
    Medical condition: Birch Pollen-induced Allergic Rhinoconjunctivitis
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004853 10001728 Allergic rhinoconjunctivitis LLT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: SE (Trial now transitioned) FR (Trial now transitioned) FI (Trial now transitioned) DE (Trial now transitioned) LT (Trial now transitioned) SK (Trial now transitioned) HU (Trial now transitioned) BG (Trial now transitioned) AT (Trial now transitioned) LV (Trial now transitioned) PL (Trial now transitioned) RO (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2011-002259-32 Sponsor Protocol Number: AN004T Start Date*: 2012-08-14
    Sponsor Name:Anergis SA
    Full Title: A multicentre, double-blind, placebo-controlled, randomized trial to assess the efficacy and tolerability of two dosing regimens of AllerT, a combination of contiguous overlapping peptides derived ...
    Medical condition: Desensitization by Specific ImmunoTherapy (SIT) in subjects allergic to birch pollen
    Disease: Version SOC Term Classification Code Term Level
    14.1 10021428 - Immune system disorders 10066093 Birch pollen allergy LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: SE (Completed) LT (Completed) DK (Completed) LV (Completed)
    Trial results: View results
    EudraCT Number: 2013-005550-30 Sponsor Protocol Number: SB/0042 Start Date*: 2014-06-10
    Sponsor Name:HAL Allergy B.V.
    Full Title: A randomized, double-blind, placebo-controlled (DBPC), parallel group study to assess the clinical efficacy and safety of SUBLIVAC FIX Birch immunotherapy in patients suffering from allergic rhinit...
    Medical condition: Moderate to severe birch pollen induced allergic rhinitis/rhinoconjunctivitis with or without mild to moderate persistent asthma.
    Disease: Version SOC Term Classification Code Term Level
    18.0 100000004870 10001726 Allergic rhinitis due to pollen LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Completed) DE (Completed) SK (Completed) BE (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2022-004082-20 Sponsor Protocol Number: T502-SIT-059 Start Date*: 2023-03-07
    Sponsor Name:Inmunotek S.L.
    Full Title: An open phase III follow-up study in patients previously treated with mannan-conjugated birch pollen allergoids or placebo in the T502-045 trial.
    Medical condition: Treatment of birch pollen-induced allergic rhinoconjunctivitis.
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004853 10001728 Allergic rhinoconjunctivitis LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2008-003861-17 Sponsor Protocol Number: AB0803 Start Date*: 2008-08-18
    Sponsor Name:Artu Biologicals Europe B.V.
    Full Title: A double-blind, randomised, placebo controlled, phase I/IIa dose escalation study to investigate the safety and tolerability of Oralgen Birch Pollen immunotherapy in patients with allergic rhinocon...
    Medical condition: Allergic rhinoconjunctivitis
    Disease: Version SOC Term Classification Code Term Level
    9.1 10001728 Allergic rhinoconjunctivitis LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: SE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2018-004205-12 Sponsor Protocol Number: 792 Start Date*: 2019-02-13
    Sponsor Name:Region Skåne
    Full Title: Methylprednisolone injection in treatment of birch pollen induced allergic rhinitis
    Medical condition: Seasonal birch pollen induced allergic rhinitis
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: SE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2012-004336-28 Sponsor Protocol Number: PQBirch203 Start Date*: 2013-08-19
    Sponsor Name:Allergy Therapeutics (UK) Ltd.
    Full Title: A multi-centre, double-blind dose-ranging study to evaluate the efficacy and safety/tolerability of Birch Modified Allergen Tyrosine-adsorbed + MPL (POLLINEX Quattro® Birch) in Subjects with season...
    Medical condition: seasonal allergic rhinoconjunctivitis due to birch pollen
    Disease: Version SOC Term Classification Code Term Level
    17.1 100000004853 10001728 Allergic rhinoconjunctivitis LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed) AT (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2013-002129-43 Sponsor Protocol Number: SMART_7 Start Date*: 2013-12-09
    Sponsor Name:Lofarma S.p.A.
    Full Title: Efficacy and Safety of sublingual immunotherapy with Allergoid LAIS®Birch-Alder tablets for patients with tree pollen-induced allergic rhinoconjunctivitis A Phase III study
    Medical condition: Patients suffering from allergic rhinoconjunctivitis
    Disease: Version SOC Term Classification Code Term Level
    17.1 100000004853 10001728 Allergic rhinoconjunctivitis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2010-020693-42 Sponsor Protocol Number: VO68.10 Start Date*: 2010-09-07
    Sponsor Name:Stallergenes S.A.
    Full Title: A randomised, double-blind, placebo-controlled, multi-national, Phase IIIb study to assess the sustained clinical effect and safety of sublingual immunotherapy administered as birch pollen extract ...
    Medical condition: Birch pollen allergic Rhinoconjunctivitis
    Disease: Version SOC Term Classification Code Term Level
    14.0 10021428 - Immune system disorders 10066093 Birch pollen allergy LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: SE (Completed) DE (Completed) SK (Completed) LV (Completed) FI (Completed) CZ (Completed) EE (Completed) LT (Completed) DK (Completed)
    Trial results: (No results available)
    EudraCT Number: 2015-000984-15 Sponsor Protocol Number: PQBirch204 Start Date*: 2015-07-13
    Sponsor Name:Allergy Therapeutics (UK) Ltd
    Full Title: A multi-centre, double-blind, placebo-controlled study to explore the safety and efficacy of Birch Modified Allergen Tyrosine adsorbed + MPL (POLLINEX® Quattro Plus 1.0 mL Birch [PQ Birch]) in subj...
    Medical condition: Seasonal allergic rhinoconjunctivitis due to birch pollen
    Disease: Version SOC Term Classification Code Term Level
    18.1 100000004853 10001728 Allergic rhinoconjunctivitis LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed) AT (Completed)
    Trial results: View results
    EudraCT Number: 2013-003095-12 Sponsor Protocol Number: AL1303AV Start Date*: 2014-03-19
    Sponsor Name:Allergopharma GmbH & Co. KG
    Full Title: Double-blind phase IV multicentre clinical trial to evaluate and compare specific and non specific effects of SCIT by use of an Environmental Challenge Chamber after treatment with Allergovit® gras...
    Medical condition: Patients suffering from seasonal allergic rhinoconjunctivitis with or without controlled asthma during the birch and grass pollen season
    Disease: Version SOC Term Classification Code Term Level
    17.1 100000004853 10001728 Allergic rhinoconjunctivitis LLT
    17.1 100000004855 10001705 Allergic asthma LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2013-003881-15 Sponsor Protocol Number: AN005T Start Date*: 2013-12-31
    Sponsor Name:Anergis SA
    Full Title: Long-term, up to 3-year follow-up of a multicentre, randomized, double-blind, placebo-controlled trial (AN004T) assessing the efficacy and tolerability of 2 dosing regimens of AllerT, a combination...
    Medical condition: Long-term follow-up of desensitization by Specific ImmunoTherapy (SIT) received during the trial AN004T in subjects allergic to birch pollen
    Disease: Version SOC Term Classification Code Term Level
    14.1 100000004870 10066093 Birch pollen allergy LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: LT (Prematurely Ended) SE (Prematurely Ended) LV (Prematurely Ended) DK (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2020-004126-32 Sponsor Protocol Number: T502-SIT-041 Start Date*: 2020-12-18
    Sponsor Name:Inmunotek S.L.
    Full Title: A prospective open follow-up study with 10 000 mTU/mL mannan-conjugated birch pollen allergoids administered subcutaneously to participants of the T502-SIT-020 trial
    Medical condition: Treatment of birch pollen-induced allergic rhinitis or rhinoconjunctivitis
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004853 10001728 Allergic rhinoconjunctivitis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2008-008448-26 Sponsor Protocol Number: 603-PG-PSC-173 Start Date*: 2009-10-20
    Sponsor Name:LETI Pharma GmbH
    Full Title: Randomized, double-blind, parallel group, multicenter study to evaluate the efficacy and safety of four doses of depigmented glutaraldehyde polymerized birch pollen allergenic extract (Depigoid® Bi...
    Medical condition: Allergic rhinitis and/or rhinoconjunctivitis, with or without intermittent asthma, caused by birch pollen.
    Disease: Version SOC Term Classification Code Term Level
    9.1 10001723 Allergic rhinitis LLT
    9.1 10039097 Rhinoconjunctivitis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) LT (Completed)
    Trial results: View results
    EudraCT Number: 2015-004821-15 Sponsor Protocol Number: TT-04 Start Date*: 2016-03-18
    Sponsor Name:ALK Abello A/S
    Full Title: Efficacy and safety of the SQ tree SLIT-tablet in subjects with moderate to severe allergic rhinitis and/or conjunctivitis induced by pollen from the birch group
    Medical condition: Allergic Rhinoconjunctivitis induced by birch pollen
    Disease: Version SOC Term Classification Code Term Level
    19.0 100000004870 10066093 Birch pollen allergy LLT
    Population Age: Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: DK (Completed) SE (Completed) CZ (Completed) FI (Completed) DE (Completed) PL (Completed) FR (Completed)
    Trial results: View results
    EudraCT Number: 2016-004827-22 Sponsor Protocol Number: BM41-VD3 Start Date*: 2017-07-25
    Sponsor Name:Academic Medical Center
    Full Title: A randomized, double-blind, placebo-controlled, double-dummy study to determine the safety/tolerability of a simultaneous subcutaneous treatment of BM41 and vitamin D 3 in patients with moderate to...
    Medical condition: moderate to severe allergic rhinitis/rhino-conjunctivitis caused by birch pollen (with or without concomitant mild to moderate persistent asthma)
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: NL (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2021-002252-36 Sponsor Protocol Number: T502-SIT-045 Start Date*: 2021-10-27
    Sponsor Name:Inmunotek S.L.
    Full Title: A prospective, randomized, double-blind placebo-controlled multicentre study with 10 000 mTU/mL mannan-conjugated birch pollen allergoids administered subcutaneously to patients with birch pollen-i...
    Medical condition: Treatment of birch pollen-induced allergic rhinitis or rhinoconjunctivitis.
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004853 10001728 Allergic rhinoconjunctivitis LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  4  5  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sat May 10 03:47:21 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA